Nader A

No ORCID on file · 3 papers in corpus
2022
Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women.
Clinical and translational science ·doi:10.1111/cts.13247

This study evaluated the effect of repeated doses of elagolix on the pharmacokinetics (PK) of omeprazole and its metabolites in healthy premenopausal female subjects. Adult premenopausal female subjects (N = 20) received a single oral dose …

article 2021
Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis
Clinical and translational science ·doi:10.1111/cts.13040

Abstract Elagolix is a novel, oral gonadotropin‐releasing hormone receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. Consi…

article 2020
Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain
CPT: pharmacometrics & systems pharmacology ·doi:10.1002/psp4.12560

Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose‐dependent manner. It is indicated for management of moderate‐to‐severe pain associated with endometriosis. A population expos…